NCT00218153

Naltrexone Augmentation of Nicotine Patch Therapy - 1

Naltrexone Augmentation of Nicotine Patch Therapy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 200 (planned)
• Sponsor: National Institute on Drug Abuse (NIDA) · NIH
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

Naltrexone Augmentation of Nicotine Patch Therapy

Detailed description

This double blind placebo controlled study is designed to determine whether naltrexone can be used to help reduce cigarette use and craving for cigarettes. Eligible participants will receive 21mg transdermal nicotine as an outpatient. In addition, participants will receive one of three doses of naltrexone (25,50 or 100mg) or a placebo and brief counseling over the course of six weeks with follow-up appointments three, six, and twelve months after the beginning of treatment.

Conditions

• Tobacco Use Disorder

Interventions

Type	Name	Description
DRUG	Naltrexone

Timeline

• Start date: 2000-11-01
• Completion: 2004-04-01
• First posted: 2005-09-22
• Last updated: 2017-01-12

Locations

2 sites across 1 country: United States